Dr. Spunt studies various types of pediatric cancers, including localized synovial sarcoma, lymphoma, sarcoma, embryonal rhabdomyosarcoma, and pediatric desmoid tumors. Her research often emphasizes how imaging techniques, like PET/MR, can lead to safer and more effective evaluations of bone tumors in children, reducing the need for excessive procedures. She is particularly interested in how factors like age and socioeconomic status affect treatment options and survival rates for young patients, aiming to improve the equity of care provided to them.
Key findings
Younger patients with localized synovial sarcoma were more likely to receive chemotherapy (48% vs. 36%) and radiotherapy (62% vs. 58%) compared to older adults, indicating age-related treatment disparities.
The study on pediatric bone tumors found that PET/MR scans are safer for children as they use less radiation and allow multiple scans in one session, improving patient comfort.
In the assessment of treatment response, diffusion-weighted MRI showed a sensitivity of 96% and specificity of 100%, while FDG PET/MRI had a sensitivity and specificity of 100%, demonstrating their effectiveness in monitoring treatment efficacy.
For embryonal rhabdomyosarcoma, targeting oxidative stress was identified as a promising treatment approach due to significant genetic changes linked to treatment challenges.
In pediatric desmoid tumors, the study found that the 5-year tumor-free rate was about 73% for younger patients and those with smaller tumors, highlighting factors that influence recovery.
Frequently asked questions
Does Dr. Spunt study treatments for pediatric cancers?
Yes, Dr. Spunt researches a variety of pediatric cancers and focuses on the effectiveness of different treatments, particularly for rare tumors.
What imaging techniques does Dr. Spunt use in her research?
She studies advanced imaging techniques, especially PET/MR and diffusion-weighted MRI, to safely and effectively monitor tumors in children.
Is Dr. Spunt's work relevant to families with children having sarcoma or lymphoma?
Yes, her research directly benefits families dealing with sarcoma or lymphoma by providing evidence on treatment effectiveness and assessing response to therapy.
What does Dr. Spunt's research reveal about treatment disparities among pediatric cancer patients?
Dr. Spunt's work indicates that factors like age and socioeconomic status significantly impact the types of treatments children receive and their survival rates.
Can Dr. Spunt's research help improve outcomes for children with rare tumors?
Yes, her studies provide valuable insights into more effective treatment options and improve the understanding of how to better care for children with rare tumors.
Publications in plain English
PET/MR of pediatric bone tumors: what the radiologist needs to know.
2023
Skeletal radiology
Padwal J, Baratto L, Chakraborty A, Hawk K, Spunt S +2 more
Plain English This study looks at using a special imaging technique called PET/MR to examine bone tumors in kids. The researchers found that this method is better than another common technique because it uses less radiation and makes it easier for young patients by combining all the necessary scans into one session. This is important because it helps doctors accurately assess bone tumors without subjecting children to extra procedures or anesthesia.
Who this helps: This benefits pediatric patients and their doctors by providing safer and more efficient imaging options.
Localized Synovial Sarcoma: A Population-Based Analysis of Treatment Patterns and Survival.
2023
Journal of adolescent and young adult oncology
Singh A, Thorpe S, Keegan T, Maguire F, Malogolowkin M +4 more
Plain English This study looked at how different factors, like age and socioeconomic status, affect the treatment choices and survival rates of patients with localized synovial sarcoma, a rare type of cancer, from 2000 to 2018 in California. The findings showed that younger patients (ages 15-39) were more likely to receive chemotherapy (48% vs. 36%) and radiotherapy (62% vs. 58%) compared to older adults. Also, patients from lower socioeconomic backgrounds had worse survival rates and received less aggressive treatment, highlighting the need to address these treatment disparities.
Who this helps: Patients with localized synovial sarcoma and healthcare providers aiming to improve treatment equity.
Plain English This study looked at how well two different types of imaging—whole-body diffusion-weighted MRI and FDG PET/MRI—can assess how children and young adults with lymphoma or sarcoma respond to cancer treatment. Researchers found a strong agreement between the two methods, with both being highly effective: diffusion-weighted MRI had a sensitivity of 96% and a specificity of 100%, while FDG PET/MRI had a sensitivity and specificity of 100%. This is important because it helps doctors determine the success of treatment early on, allowing for timely adjustments if needed.
Who this helps: Patients undergoing treatment for lymphoma or sarcoma.
Targeting oxidative stress in embryonal rhabdomyosarcoma.
2013
Cancer cell
Chen X, Stewart E, Shelat AA, Qu C, Bahrami A +42 more
Plain English This study looked at embryonal rhabdomyosarcoma (ERMS), a type of cancer that affects soft tissue and resembles developing muscle. Researchers found that ERMS has a lot of genetic changes linked to the RAS/NF1 pathway, making it riskier to treat. They discovered that targeting oxidative stress could be a promising treatment approach for this cancer.
Who this helps: This research helps patients with embryonal rhabdomyosarcoma by identifying new treatment options.
Surgical treatment of pediatric desmoid tumors. A 12-year, single-center experience.
2013
Annals of surgical oncology
Soto-Miranda MA, Sandoval JA, Rao B, Neel M, Krasin M +4 more
Plain English This study looked at how to treat pediatric desmoid tumors (PDTs) in children over 12 years at St. Jude Children's Research Hospital. They analyzed the results from 39 patients, discovering that while 97% were free of the disease one year after surgery, that number dropped to 73% after five years. They found that older patients and larger tumors were more likely to come back, but the way the tumor was removed didn’t impact recurrence rates.
Who this helps: This research benefits doctors and patients with pediatric desmoid tumors by providing insights on surgical treatment and outcomes.
Heike E Daldrup-Link John A Sandoval Andrew M Davidoff Amisha Singh Steven Thorpe Theresa Keegan Frances Maguire Marcio Malogolowkin Renata Abrahão Janai Carr-Asher
Physician data sourced from the
NPPES NPI Registry
.
Publication data from
PubMed
.
Plain-English summaries generated by AI.
Not medical advice.